

Appendix Table 1. Three major prognostic indicators of patients with and without comorbidities

	Severe cases (%)	Cases with composite endpoints (%)	Fatality cases (%)
HTN (n=269)	156 (58)	101 (38)	55 (20)
DM (n=74)	41 (55)	20 (27)	15 (20)
HTN+DM (n=115)	82 (71)	52 (45)	22 (19)
Others (n=573)	222 (39)	109 (19)	73 (13)
Total (n=1031)	501 (49)	282 (27)	165 (16)

Abbreviations:

HTN: hypertension

DM: diabetes mellitus

Appendix Table 2. The odds ratio of case fatality rate for elderly patients, male patients, and patients with COPD, HTN, DM, CHD, stroke, cancer, smoking history

	Number of patients (%)	OR (univariable regression)	95% CI	P-value	OR (multivariable regression)	95% CI	P-value	OR (multivariable regression)	95% CI	P-value
The elderly	462 (44.8)	3.33	2.33-4.76	0.000	2.94	2.00-4.33	0.000	2.95	2.00-4.33	0.000
Male	538 (52.2)	2.86	1.98-4.13	0.000	2.47	1.65-3.70	0.000	2.45	1.64-3.66	0.000
COPD	39 (3.7)	4.93	2.56-9.47	0.000	2.69	1.32-5.49	0.006	2.72	1.33-5.54	0.006
HTN	384 (37.2)	1.59	1.14-2.23	0.007	1.05	0.72-1.54	0.800	1.02	0.69-1.51	0.927
DM	189 (18.3)	1.36	0.91-2.04	0.139				1.22	0.78-1.92	0.381
CHD	84 (8.1)	2.61	1.59-4.28	0.000	2.04	1.18-3.55	0.011	1.98	1.14-3.45	0.016
Stroke	22 (2.1)	2.51	1.01-6.26	0.048	2.70	1.00-7.31	0.050	2.68	0.99-7.25	0.053
Cancer	29 (2.8)	5.26	2.49-11.12	0.000	8.01	3.55-18.07	0.000	8.14	3.60-18.38	0.000
Smoking history	105 (10.1)	3.22	2.07-5.02	0.000	2.05	1.25-3.38	0.005	2.09	1.27-3.45	0.004

DM was excluded from the multivariable logistic regression analysis due to the fact that it showed no relation to case fatality in the univariable logistic regression analysis.

Boldface of P-value indicates statistical significance ($p \leq 0.05$).

Abbreviations:

CHD: coronary atherosclerotic heart disease

DM: diabetes mellitus

HTN: hypertension

Appendix Table 3. Comparison of illness condition among senile and non-senile patients with and without hypertension

	Age<65		P-value	Age>=65		P-value
	non-hypertension (n=419)	hypertension (n=150)		non-hypertension (n=228)	hypertension (n=234)	
Age (SD), y	48.7 (11.5)	55.2 (7.5)	0.000	71.4 (5.6)	73.4 (6.8)	0.001
Female (%)	215 (51.3)	67 (44.7)	0.162	102 (44.7)	109 (46.6)	0.691
OOS (SD), %	94.7 (7.2)	93.8 (6.1)	0.171	92.6 (8.1)	91.8 (8.5)	0.316
HR (SD), beats/min	91.6 (16.5)	92.6 (18.0)	0.541	91.1 (17.3)	90.8 (15.9)	0.843
SBP (SD), mmHg	125.4 (17.5)	134.2 (18.6)	0.000	132.4 (17.8)	138.9 (19.7)	0.000
DBP (SD), mmHg	79.5 (11.5)	82.7 (12.6)	0.006	79.4 (12.4)	81.3 (13.0)	0.105
MAP (SD), mmHg	94.8 (12.3)	99.8 (13.2)	0.000	97.1 (13.1)	100.5 (13.3)	0.005
NEU (SD), /µL	4.3×10^3 (3.1×10^3)	4.9×10^3 (3.3×10^3)	0.037	5.1×10^3 (3.3×10^3)	5.7×10^3 (4.1×10^3)	0.072
LYM (SD), /µL	1.3×10^3 (0.6×10^3)	1.2×10^3 (0.6×10^3)	0.090	1.0×10^3 (0.5×10^3)	1.0×10^3 (0.5×10^3)	0.507
PLT (SD), $\times 10^3/\mu\text{L}$	240.4 (99.4)	238.7 (99.9)	0.859	227.6 (103.0)	222.8 (95.8)	0.604
CRP (SD), mg/dL	3.6 (5.5)	4.2 (5.9)	0.305	5.3 (5.4)	6.6 (6.5)	0.023
IL-6 (SD), pg/ml	22.0 (78.7)	29.7 (54.9)	0.321	53.0 (178.7)	41.9 (72.3)	0.450
LDH (SD), U/L	293.1 (175.2)	308.3 (154.0)	0.348	335.2 (191.5)	375.7 (231.9)	0.042
D-dimer (SD), µg/ml	2.0 (4.8)	2.4 (4.7)	0.427	3.9 (6.3)	4.1 (6.7)	0.670
eGFR (SD), ml/min	100.3 (17.7)	93.3 (16.8)	0.000	80.0 (17.1)	71.7 (20.8)	0.000
CCIR (%)	147 (35.1)	73 (48.7)	0.003	116 (50.9)	165 (70.5)	0.000
CFR1^a (%)	37 (8.8)	14 (9.3)	0.853	51 (22.4)	63 (26.9)	0.256
CFR2^b (%)	37 (25.2)	14 (19.2)	0.321	51 (44.0)	63 (38.2)	0.331

CFR1^a: The dead in the group/The total in the group

CFR2^b: The dead in the group /The severe cases in the group

Boldface of P-value indicates statistical significance ($p<0.05$).

Abbreviations:

CCIR: case-critically ill rate

CFR: case-fatality rate

CRP: C-reactive protein

DBP: diastolic blood pressure

eGFR: glomerular filtration rate

HR: heart rate

IL-6: Interleukin 6

LDH: lactate dehydrogenase

LYM: lymphocyte

MAP: mean arterial pressure

NEU: neutrophil

OOS: oximeter oxygen saturation

PLT: platelet

SBP: systolic blood pressure

Appendix Table 4. Comparison of in-hospital treatment of CCB and prognosis among different groups

		CCB	non-CCB	P-value
Total (n=1031)	Age>=65y (%)	125 (64)	337 (40)	<0.001
	Male (%)	100 (51)	438 (52)	0.717
	OOS (SD), %	93.5 (6.3)	93.5 (7.9)	0.989
	HTN (%)	166 (85)	218 (26)	<0.001
	Other underlying diseases#	86 (44)	276 (33)	0.004
	CFR (%)	32/196 (16)	133/835 (16)	0.891
	LOS (SD), d	23.7 (10.3)	20.8 (10.0)	0.001
Low-risk* (n=328)	CFR (%)	0/14 (0)	10/314 (3)	1.000
	LOS (SD), d	13.2 (7.5)	17.9 (9.3)	0.066
Age>=65y (n=462)	CFR (%)	27/125 (22)	87/337 (26)	0.350
	LOS (SD), d	26.0 (9.9)	23.7 (9.0)	0.033
HTN (n=384)	CFR (%)	30/166 (18)	47/218 (22)	0.398
	LOS (SD), d	24.5 (10.2)	22.3 (10.1)	0.067
Severe cases** with IKF (n=73)	CFR (%)	12/23 (52)	32/50 (64)	0.337
	LOS (SD), d	31.9 (6.3)	28.6 (12.2)	0.339
Severe cases** without IKF (n=271)	CFR (%)	13/57 (23)	76/214 (36)	0.069
	LOS (SD), d	26.5 (10.0)	24.8 (9.9)	0.338

refer to cases combining with any one of the underlying diseases including DM, CHD, COPD, cancer, and smoking history

* refer to cases with non-HTN, age<65y, and OOS>93

** refer to cases with OOS<=93

Boldface of P-value indicates statistical significance (p<0.05).

Abbreviations:

CCB: calcium channel blockers

CFR: case-fatality rate

COPD: chronic obstructive pulmonary disease

HTN: hypertension

IKF: impaired kidney function

LOS: length of stay

OOS: oximeter oxygen saturation

Appendix Table 5. Comparison of illness condition between patients with hypertension taking CCB and not taking CCB

	CCB (n=166)	non-CCB (n=218)	P-value
Age (SD), y	68.0 (10.6)	65.1 (11.8)	0.014
Female (%)	78 (46.9)	98 (44.9)	0.692
DM (%)	41 (24.7)	74 (33.9)	0.050
CHD (%)	29 (17.5)	37 (17.0)	0.898
IKF (%)	41 (24.7)	35 (16.1)	0.035
Smoking history (%)	18 (10.8)	35 (16.1)	0.142
COPD (%)	5 (3.0)	12 (5.5)	0.239
Cancer (%)	5 (3.0)	5 (2.3)	0.909
RASI (%)	31 (18.7)	18 (8.3)	0.002
OOS (SD), %	93.2 (6.0)	92.1 (8.7)	0.131
HR (SD), beats/min	90.7 (15.0)	91.7 (18.8)	0.543
SBP (SD), mmHg	138.5 (19.3)	136.0 (19.4)	0.216
DBP (SD), mmHg	82.9 (12.5)	81.0 (13.0)	0.160
MAP (SD), mmHg	101.4 (12.8)	99.3 (13.5)	0.131
CRP (SD), mg/dL	5.6 (6.5)	5.7 (6.3)	0.918
LDH (SD), U/L	346.4 (208.6)	351.4 (206.7)	0.814
eGFR (SD), ml/min	78.1 (22.6)	81.7 (21.4)	0.111
CCIR (%)	103 (62.0)	135 (61.9)	0.981
CFR (%)	30 (18.0)	47 (21.5)	0.398

Boldface of P-value indicates statistical significance (p<=0.05).

Abbreviations:

DM: diabetes mellitus

CHD: coronary atherosclerotic heart disease

IKF: impaired kidney function

OOS: oximeter oxygen saturation

HR: heart rate

SBP: systolic blood pressure

DBP: diastolic blood pressure

MAP: mean arterial pressure

CRP: C-reactive protein

LDH: lactate dehydrogenase

eGFR: glomerular filtration rate

CCIR: case-critically ill rate

CFR: case-fatality rate

SI conversion factors:

- To convert NEU to $\times 10^9/\text{L}$, multiply values by 0.001.
- To convert LYM to $\times 10^9/\text{L}$, multiply values by 0.001.
- To convert PLT to $\times 10^9/\text{L}$, multiply values by 1.
- To convert CRP to mg/L, multiply values by 10.
- To convert LDH to $\mu\text{kat}/\text{L}$, multiply values by 0.0167.
- To convert D-dimer to nmol/L, multiply values by 5.476.

Appendix Table 6. The odds ratio of case fatality rate for patients with hypertension taking CCB

	OR (multivariable regression)	95% CI	P-value
Age	1.05	1.02-1.08	0.001
Male	3.54	1.85-6.78	<0.001
Smoking history	1.90	0.93-3.88	0.081
DM	0.85	0.46-1.59	0.617
IKF	2.33	1.22-4.48	0.011
COPD	1.00	0.31-3.18	0.994
Cancer	1.53	0.29-8.17	0.619
RASI	0.94	0.37-2.36	0.891
CCB	0.67	0.37-1.20	0.176

Boldface of P-value indicates statistical significance (p<0.05).

Abbreviations:

CCB: calcium channel blockers

COPD: chronic obstructive pulmonary disease

DM: diabetes mellitus

IKF: impaired kidney function

RASI: renin-angiotensin-aldosterone system inhibitors

Appendix Table 7. The odds ratio of case fatality rate for severe cases without IKF

	OR (univariable regression)	95%CI	P-value	OR (multivariable regression)	95%CI	P-value
Age>=65y	2.49	1.46-4.24	0.001	2.84	1.56-5.17	0.001
Male	2.41	1.39-4.20	0.002	2.52	1.36-4.67	0.003
HTN	0.58	0.34-0.97	0.038	0.64	0.33-1.22	0.174
DM	0.89	0.49-1.60	0.691			
CHD	2.24	1.02-4.93	0.045	2.47	1.01-6.03	0.047
COPD	1.86	0.65-5.29	0.247			
Smoking history	2.00	0.97-4.13	0.062			
Cancer	10.13	2.14-47.93	0.004	15.76	2.93-84.78	0.001
CCB	0.54	0.27-1.06	0.072	0.42	0.18-0.99	0.046

DM, COPD, and smoking history were excluded from the multivariable logistic regression analysis due to the fact that they showed no relation to case fatality in the univariable logistic regression analysis.

Boldface of P-value indicates statistical significance ($p<0.05$).

Abbreviations:

CCB: calcium channel blockers

CHD: coronary atherosclerotic heart disease


COPD: chronic obstructive pulmonary disease

DM: diabetes mellitus

HTN: hypertension

Summarized mode pattern related to hypertension, ACE2, LDH, and eGFR

A large number of published studies demonstrated that LDH was the primary laboratory indicator for early prediction of COVID-19 progression and death. A Hangzhou study published online found that LDH was the only laboratory indicator that showed a significant change in hospitalized patients after antiviral treatment, indicating that the change in this indicator was related to the viral load.^[8] An Iran and a Brazilian study showed that the average levels of LDH of COCID-19 inpatients were 616.77 ± 314.22 U/L and 948 ($810.0-1139.8$) U/L respectively,^[20, 21] which were significantly higher than the results shown in Europe, America, Eastern Asia and our retrospective cohort study (323.32 ± 192.77 U/L). The differences suggest that the elevation of LDH level may be quite different among different ethnic groups, and the absolute value of LDH may be in connection with the expression of ACE2 and viral tolerance of patients themselves. Based on the above findings, we summarized the mode pattern associated with hypertensive patients in aggravated condition and ACE2 expression.



Abbreviations:

HTN: hypertension

ACE2: angiotensin-converting enzyme 2

LDH: lactate dehydrogenase

eGFR: glomerular filtration rate